Авторы

  • Mamatov L.B., Abdugapparov F.B.
  • Eshmuradov X.I.

Ключевые слова:

MDR-TB, viral hepatitis “C” and “B”, TB treatment outcome

Библиографические ссылки

Abdugapparov F. et al. Diagnostic procedures, diagnoses, and treatment outcomes of patients with presumptive tuberculosis pleural effusion in uzbekistan //International Journal of Environmental Research and Public Health. – 2021. – Т. 18. – №. 11. – С. 5769.

World Health Organization Geneva, Switzerland: WHO; 2021. Global tuberculosis report, 2021.

Centre for Disease Analysis World Health Organization. Global hepatitis report, 2017. Geneva, Switzerland: WHO; 2018. Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by World Health Organization region, 2015.

Chang TE, et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis. J Chin Med Assoc. 2018;81(2):111–118. doi: 10.1016/j.jcma.2017.10.002.

Zoratti MJ, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis. EClinicalMedicine. 2020;18:100237. doi: 10.1016/j.eclinm.2019.12.007.

World Health Organization Geneva, Switzerland: WHO; 2018. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.

World Health Organization Geneva, Switzerland: WHO; 2021. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report, 2020.

Melikyan N, et al. Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe. Open Forum Infect Dis. 2021;8(2):ofaa653. doi: 10.1093/ofid/ofaa653.

Musso M, et al. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. BMC Infect Dis. 2019;19(1):882. doi: 10.1186/s12879-019-4494-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Tunesi S, et al. Safety and efficacy of co-administration of direct-acting antivirals for HCV and drugs for MDR-TB: a multi-country TBnet and ESG MYC cohort study. Abstract no 2591 presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 9–12 July 2021.

Tunesi S, et al. Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. J Infect. 2022; 84(6):834–872. doi: 10.1016/j.jinf.2022.03.004.

European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020; 73(5):1170–1218. doi: 10.1016/j.jhep.2022.10.006.

Kempker RR, et al. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019; 63 (12) doi: 10.1128/AAC.01215-19. e01215-19.

Lee SS, et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(6):800–805. doi: 10.5588/ijtld.15.0668.

Chen L, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):295. doi: 10.1186/s1287 9-018-3192-8.

Lui GCY, et al. Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B coinfection. Clin Infect Dis. 2020;70(4):660–666. doi: 10.1093/cid/ciz241.